Abbott announced that the company's Eterna SCS system ? the small implantable, rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain, has been used for the first time in Canada. The inaugural use case of the Eterna SCS system took place at Hôpital de l'Enfant-Jésus hospital in Quebec City.

The Eterna SCS system uses Abbott's proprietary BurstDR stimulation, the only SCS technology with the high level of clinical evidence (level 1A.) Abbott's proprietary BurstDR therapy is proven to reduce pain by 23% more than traditional tonic stimulation without the tingling sensation. Approved by Health Canada in 2023, Abbott developed the Eterna SCS System based on extensive studies with patients, physicians, and caregivers to understand the unmet needs of people living with chronic pain. The studies found that people wanted small, comfortable implants which don't need to be charged daily.

Abbott designed the Eterna SCS System to be recharged wirelessly at a frequency of five times per year under normal use, making it the lowest recharge burden platform on the market. The Eterna SCS System is currently the small device available, designed for implant site comfort, and features Abbott's BurstDR stimulation, which mimics natural firing patterns found in the brain to deliver superior pain relief over traditional tonic stimulation.